These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19755294)

  • 1. Late stent thrombosis: the Damocle's sword of drug eluting stents?
    Rodriguez AE; Rodriguez-Granillo GA; Palacios IF
    EuroIntervention; 2007 Feb; 2(4):512-7. PubMed ID: 19755294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?
    Valgimigli M; Airoldi F; Zimarino M
    J Cardiovasc Med (Hagerstown); 2009 Oct; 10 Suppl 1():S17-26. PubMed ID: 19851216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Stent thrombosis in the era of drug-eluting stents].
    Wöhrle J
    Herz; 2007 Aug; 32(5):411-8. PubMed ID: 17687531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting versus bare metal stenting in acute myocardial infarction. A clinical review.
    Jones WS; Washam JB; Meine TJ; Patel MR
    Minerva Cardioangiol; 2009 Oct; 57(5):585-95. PubMed ID: 19838149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.
    Rodriguez AE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):561-76. PubMed ID: 19712016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The conundrum of late and very late stent thrombosis following drug-eluting stent implantation.
    Garg P; Mauri L
    Curr Opin Cardiol; 2007 Nov; 22(6):565-71. PubMed ID: 17921745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stent thrombosis in the era of drug eluting stents.
    Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
    Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives.
    Jaffe R; Strauss BH
    J Am Coll Cardiol; 2007 Jul; 50(2):119-27. PubMed ID: 17616295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
    Waksman R; Pakala R
    EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Optimal platelet inhibition after coronary stent implantation. Current status].
    Silber S; Hoffmeister HM; Bode C
    Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label use of stents: bare-metal versus drug-eluting stents.
    Girod JP; Mulukutla SR; Marroquin OC
    Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1095-106. PubMed ID: 18793112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting stents: towards new endpoints.
    Presbitero P; Zavalloni D; Rossi ML; Pagnotta P; Belli G; Gasparini GL; Corrada E; Milone F
    Minerva Cardioangiol; 2006 Oct; 54(5):521-37. PubMed ID: 17019391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of drug eluting stents versus bare metal stents in ST-elevation myocardial infarction: a contemporary review.
    Bokhoor PI; Lee MS
    Minerva Cardioangiol; 2011 Feb; 59(1):49-59. PubMed ID: 21285931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
    Qasim A; Cosgrave J; Latib A; Colombo A
    Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.
    Lüscher TF; Steffel J; Eberli FR; Joner M; Nakazawa G; Tanner FC; Virmani R
    Circulation; 2007 Feb; 115(8):1051-8. PubMed ID: 17325255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.